Product Development Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Cellect Biomed Ltd. – Joint Product Development Agreement (July 7th, 2016)

THIS JOINT PRODUCT DEVELOPMENT AGREEMENT ("Agreement"), effective as of the 17th day of June, 2015 ("Effective Date"), is made and entered into by and between CELLECT BIOMED LTD., an Israeli corporation with its principal office located at 10 Hataas Street, Kfar Saba, Israel ("Cellect"), and ENTEGRIS, INC., a Delaware corporation with its principal office located at 129 Concord Road Billerica, MA 01821 ("Entegris"). Each of Cellect and Entegris are sometimes hereinafter referred to as a "Party" and collectively as the "Parties".

Cellect Biomed Ltd. – Joint Product Development Agreement (April 8th, 2016)

THIS JOINT PRODUCT DEVELOPMENT AGREEMENT ("Agreement"), effective as of the 17th day of June, 2015 ("Effective Date"), is made and entered into by and between CELLECT BIOMED LTD., an Israeli corporation with its principal office located at 10 Hataas Street, Kfar Saba, Israel ("Cellect"), and ENTEGRIS, INC., a Delaware corporation with its principal office located at 129 Concord Road Billerica, MA 01821 ("Entegris"). Each of Cellect and Entegris are sometimes hereinafter referred to as a "Party" and collectively as the "Parties".

Nxt-ID, Inc. – Master Product Development Agreement (January 4th, 2016)

This Master Product Development Agreement (the "Agreement"), dated as of December 31, 2015 (the "Effective Date"), is by and between Nxt-ID, Inc., a Delaware corporation with offices located at 288 Christian Street, Oxford, Connecticut 06478 ("Developer"), and WorldVentures Holdings, LLC, a Nevada limited liability company with offices located at 5100 Tennyson Parkway, Plano, Texas 75024 ("Customer").

Quantum Materials Corp. – Quantum Materials Corp Signs Funded Product Development Agreement With Leading Optical Film Manufacturer (September 22nd, 2015)

San Marcos, TX - September 22, 2015 - -- Leading North American quantum dot manufacturer Quantum Materials Corp ("QMC" or the "Company") (OTCQB:QTMM) today announced that the company has executed a funded product development agreement with a leading global optical film manufacturer.

Corgenix Medical – CORGENIX MEDICAL CORPORATION HAS REQUESTED THAT THE PORTIONS OF THIS DOCUMENT DENOTED BY BRACKETS AND ASTERISKS BE ACCORDED CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934. TECHNOLOGY TRANSFER, LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (August 20th, 2014)

This agreement (the Agreement) is effective August 15, 2014 by and between Corgenix Medical Corporation a corporation organized and existing under the laws of the State of Nevada and having its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado, 80020 (hereinafter referred to as Corgenix); and Eli Lilly and Company, a corporation organized and existing under the laws of Indiana and having its principal place of business at Lilly Corporate Center, Indianapolis, IN (hereinafter referred to as Lilly). Corgenix and Lilly are also herein referred to as a Party or, collectively, the Parties.

Lifelogger Technologies Corp – Product Development Agreement (August 12th, 2014)

THIS PRODUCT DEVELOPMENT AGREEMENT (the "Agreement") is made effective as of January 7, 2014 by and between Matrico Holdings, Ltd., a Belize corporation located at Suite 701, Tung Hip Commercial Building, No. 244-248 Des Voeux Road Central, Hong Kong (the "Company"), and Lifelogger Technologies Corp., a Nevada corporation located at 11380 Prosperity Farms Road, #221E, Palm Beach Gardens, Florida 33410 ("Contractor"). For purposes hereof, the Company and Contractor may collectively be referred to as the "Parties."

Lifelogger Technologies Corp – Addendum to Product Development Agreement (August 12th, 2014)

THIS ADDENDUM TO PRODUCT DEVELOPMENT AGREEMENT (the "Addendum") is made effective as of the June 1, 2014 by and between Matrico Holdings, Ltd., a company located in Hong Kong (the "Company") and Lifelogger Technologies Corp., a Nevada corporation ("Contractor"); collectively referred to as the "Parties".

Dipexium Pharmaceuticals, Inc. – Product Development Agreement (February 6th, 2014)

This Product Development Agreement (this Agreement) is effective January 1, 2014 (the Effective Date) and is between RRD International, LLC, a Delaware limited liability company with offices at (hereinafter RRD) and Dipexium Pharmaceuticals, LLC, a Delaware limited liability company with offices at (hereinafter Dipexium). Each of RRD and Dipexium is a Party and together they are the Parties. When signed by both Parties, this Agreement will set forth the terms and conditions under which RRD agrees to provide certain product development services to Dipexium as set forth herein.

Joint Research and Product Development Agreement (October 7th, 2013)

This Joint Research and Product Development Agreement is entered into effective May 31, 2012 (the "Effective Date"), between Sumitomo Precision Products Co., Ltd., a Japanese corporation having a place of business at 1-10 Fuso-cho, Amagasaki, Hyogo 660-0891 Japan, (hereinafter "SPP"), and Visualant, Incorporated a corporation under the laws of the State of Nevada having a business address of 500 Union Street, Suite 406, Seattle, Washington, 98101, and subsidiaries and affiliates (hereinafter "VISUALANT").

Amendment to Joint Research and Product Development Agreement (September 16th, 2013)

This Amendment to the Joint Research and Product Development Agreement ("Amended Agreement") dated May 31, 2012 is entered into effective March 29, 2013 (the "Effective Date"), between Sumitomo Precision Products Co., Ltd., a Japanese corporation having a place of business at 1-10 Fuso-cho, Amagasaki, Hyogo 660-0891 Japan, (hereinafter "SPP"), and Visualant, Incorporated a corporation under the laws of the State of Nevada having a business address of 500 Union Street, Suite 420, Seattle, Washington, 98101, and subsidiaries and affiliates (hereinafter "VISUALANT").

Joint Research and Product Development Agreement (September 16th, 2013)
Minerco Resources, Inc. – Premium Product Development Agreement (June 19th, 2013)

This Premium Product Development Agreement (the "Agreement") is made as of the 26th day of February, 2012 (the "Effective Date"), by and between Power Brands, a California Limited Liability Company ("Power Brands") and Level 5 Beverage Company, Inc., a subsidiary of Minerco Resources, Inc., 20 Trafalgar Square, Suite 455, Nashua, NH 03063 (the "Client").

Amendment to Joint Research and Product Development Agreement (April 4th, 2013)

This Amendment to the Joint Research and Product Development Agreement ("Amended Agreement") dated May 31, 2012 is entered into effective March 29, 2013 (the "Effective Date"), between Sumitomo Precision Products Co., Ltd., a Japanese corporation having a place of business at 1-10 Fuso-cho, Amagasaki, Hyogo 660-0891 Japan, (hereinafter "SPP"), and Visualant, Incorporated a corporation under the laws of the State of Nevada having a business address of 500 Union Street, Suite 420, Seattle, Washington, 98101, and subsidiaries and affiliates (hereinafter "VISUALANT").

Minerco Resources, Inc. – Premium Product Development Agreement (March 25th, 2013)

This Premium Product Development Agreement (the "Agreement") is made as of the ____ day of __________, 2012 (the "Effective Date"), by and between Power Brands, a California Limited Liability Company ("Power Brands") and _________________ , whose address is _______________________, (the "Client").

Digital Blue Dog, Inc. – Product Development Agreement (September 19th, 2012)

THIS AGREEMENT is made and entered into as of ____ day of May, 2012, by and between Feed the Dog, LLC, a New Jersey limited liability company ("Feed the Dog") and Digital Blue Dog, Inc. a Florida corporation ("Digital Blue Dog").

Joint Research and Product Development Agreement (June 4th, 2012)

This Joint Research and Product Development Agreement is entered into effective May 31, 2012 (the Effective Date), between Sumitomo Precision Products Co., Ltd., a Japanese corporation having a place of business at 1-10 Fuso-cho, Amagasaki, Hyogo 660-0891 Japan, (hereinafter SPP), and Visualant, Incorporated a corporation under the laws of the State of Nevada having a business address of 500 Union Street, Suite 406, Seattle, Washington, 98101, and subsidiaries and affiliates (hereinafter VISUALANT).

New Energy Systems Group. – New Trent Inc Product Development Agreement With SHENZHEN ANYTONE TECHNOLOGY CO., LTD This Product Development Agreement, Herein Referred to as ("Agreement"), Is Made by and Between SHENZHEN ANYTONE TECHNOLOGY CO., LTD (February 23rd, 2012)

("hereinafter referred as ANT") located at 5F, 51 Building. No. 5 Qiongyu RD, High-tech industrial park, Nanshan district, Shenzhen, China. 518057

Corgenix Medical – First Amended and Restated Joint Product Development Agreement (August 2nd, 2011)

This First Amended and Restated Joint Product Development Agreement (Agreement) is made and entered into on this 28th day of July, 2011 (Effective Date), by and among Corgenix Medical Corporation, a Nevada corporation (Corgenix), with its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado 80020, Financiere Elitech SAS, a societe par actions simplifiee organized under the laws of France (Elitech), with its principal place of business at 12-12bis, rue Jean Jaures, 92800 Puteaux, France, and Wescor, Inc., a Utah corporation (Wescor), with its principal place of business at 370 West 1700 South, Logan, Utah 84321. Each of Corgenix, Elitech and Wescor are sometimes referred to in this agreement individually as a Party and, collectively, as the Parties.

Product Development Agreement (January 18th, 2011)

This PRODUCT DEVELOPMENT AGREEMENT (Agreement), is made this January 11, 2011 (the Effective Date) by and between TechniScan, Inc., a Delaware corporation having offices at 3216 South Highland Dr., Suite 200, Salt Lake City, Utah 84106 on behalf of itself and its affiliates (collectively, TechniScan) and Womens3D, Inc., a Delaware corporation, having offices at 4917 S. Congress, Austin, Texas 78745 (Womens3D and together with TechniScan, each a Party and collectively, the Parties).

SentiSearch, Inc. – Project Research and Product Development Agreement (November 15th, 2010)

This Project Research and Product Development Agreement (the "Agreement") is made and entered into as of September 15, 2010 (the "Effective Date") by and among Bayer CropScience AG, a German corporation having its principal place of business at Alfred-Nobel-Str. 50, 40789 Monheim, Germany ("Bayer"), and SentiSearch, Inc., a Delaware incorporated company having its principal place of business at 1217 South Flagler Drive, West Palm Beach, FL 33401, U.S.A. ("SentiSearch").

Corgenix Medical – Joint Product Development Agreement (July 16th, 2010)

This Joint Product Development Agreement (Agreement) is made and entered into on this 16th day of July, 2010 (Effective Date), by and between Corgenix Medical Corporation, a Nevada corporation (Corgenix), with its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado 80020, and Financiere Elitech SAS, a societe par actions simplifiee organized under the laws of France (Elitech), with its principal place of business at 12-12bis, rue Jean Jaures, 92800 Puteaux, France. Corgenix and Elitech are sometimes referred to in this agreement individually as a Party and, collectively, as the Parties.

VGambling Inc. – Second Product Development Agreement (May 10th, 2010)

Based on the rule of CONTRACT LAW OF THE PEOPLE'S REPUBLIC OF CHINA, the two side made the following Second Product Development Agreement after consultations.

Multicell Technologies – Confidential Treatment Has Been Requested With Respect to Certain Portions of This Exhibit Pursuant to a Request for Confidential Treatment Under Rule 24b-2 Promulgated Under the Securities Exchange Act of 1934, as Amended. Omitted Portions Have Been Filed Separately With the Securities and Exchange Commission. COOPERATIVE RESEARCH AND PRODUCT DEVELOPMENT AGREEMENT (March 19th, 2009)

This AGREEMENT ("Agreement"), effective as of March 17, 2009, ("Effective Date") is between MAXIM BIOTECH, INC., a California corporation ("Maxim"), and MULTICELL TECHNOLOGIES, INC., a Delaware Corporation ("MultiCell").

Cpc Of America – Product Development Agreement (March 13th, 2009)
ARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER Product Development Agreement Focused on ARQ 197, C-Met Inhibitor, With Discovery Collaboration Directed Toward Novel Kinase Inhibitors; Total Cash Upfront to ArQule Is $75 Million; ArQules Conference Call Scheduled Today (November 10) at 9:00 AM Eastern Time (November 10th, 2008)

Woburn, MA, November 10, 2008 and Tokyo, Japan, November 11, 2008 ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo Co., Ltd. (TSE: 4568) today announced that they have entered into two agreements that form the basis of a strategic relationship for the development and discovery of novel oncology therapeutics.

PRODUCT DEVELOPMENT AGREEMENT BETWEEN COREPHARMA LLC AND KING PHARMACEUTICALS, INC. And KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. Note: Certain Material Has Been Redacted From This Document and Filed Separately With the SEC Pursuant to a Request for Confidential Treatment Under Rule 24b-2. The Locations of These Redactions Are Indicated Throughout the Document by the Following Marking: [***]. (August 7th, 2008)

THIS PRODUCT DEVELOPMENT AGREEMENT (Agreement) is made on June 18, 2008 (the Effective Date) by and between COREPHARMA LLC, a limited liability company, incorporated under the laws of New Jersey (Core), and KING PHARMACEUTICALS, INC., a corporation incorporated under the laws of Tennessee (KPI), and KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC., a Delaware corporation and wholly owned subsidiary of KPI (King R&D, and together with KPI, King).

Universal Solar – Prototype Product Development Agreement (May 9th, 2008)
Scivanta Medical Cor – Product Development Agreement Pda-001 (August 23rd, 2007)

This Agreement made and entered into between Scivanta Medical Corporation, with its principal office at 215 Morris Avenue, Spring Lake, New Jersey 07762 ("CUSTOMER") and Sparton Medical Systems, a business group of Sparton Electronics Florida, Inc., a Florida Corporation, with an office at P. O. Box 788, 5612 Johnson Lake Road, DeLeon Springs, Florida 32130 ("SMS").

Scivanta Medical Cor – Scivanta Medical Corporation Product Development Agreement (July 3rd, 2007)

This Product Development Agreement (this "Agreement") is made by and between Ethox International, Inc. ("Ethox"), a New York corporation with a principal place of business at 251 Seneca Street, Buffalo, NY 14204, and Scivanta Medical Corporation ("Scivanta") a Nevada corporation with a principal place of business at 215 Morris Avenue, Spring Lake, NJ 07762, as follows:

Aspect Medical Systems, Inc. – Amendment No. 2 to Oem Product Development Agreement (February 7th, 2007)

This AMENDMENT NO. 2 (Amendment No. 2) is made this 5th day of February, 2007, by and between Aspect Medical Systems, Inc., a Delaware corporation (AMS), and Boston Scientific Corporation, a Delaware corporation (BSC), and amends that certain OEM PRODUCT DEVELOPMENT AGREEMENT, dated as of August 7, 2002, among AMS and BSC (the Agreement), as amended by that certain Amendment No. 1 to OEM PRODUCT DEVELOPMENT AGREEMENT, dated as of January 31, 2005, among AMS and BSC (Amendment No. 1). Capitalized terms used herein but not otherwise defined herein shall have the meaning ascribed to them in the Agreement.

Second Amended and Restated Product Development Agreement (November 8th, 2006)

This SECOND AMENDED AND RESTATED PRODUCT DEVELOPMENT AGREEMENT, dated as of July 7, 2006, is made and entered into by and between Toshiba Corporation, a Japanese corporation with a principal place of business at 1-1, Shibaura 1-chome, Minato-ku, Tokyo 105-8001, Japan (Toshiba), and SanDisk Corporation, a Delaware corporation with a principal place of business at 601 McCarthy Boulevard, Milpitas, CA 95035, U. S. A. (SanDisk, and collectively with Toshiba, the Parties).

400 Chestnut Ridge Road Woodcliff Lake, NJ 07677 201-930-3300 N E W S R E L E a S E CONTACT: Carol A. Cox, 201-930-3720 EMAIL: [email protected] (August 15th, 2006)

Barr and Shire Sign Three Agreements: A Product Acquisition Agreement for ADDERALL(r); A Product Development Agreement; and A Settlement and License Agreement for ADDERALL XR(r)

Legacy Technology Holdings, Inc. – Contract (December 9th, 2005)

EXHIBIT 10.1 NEW PRODUCT DEVELOPMENT AGREEMENT EXHIBIT 10.1 NEW PRODUCT DEVELOPMENT AGREEMENT Effective this July 19, 2005 Between: Neptune Technologies & Bioressources Inc., having a principal place of business at 500 Saint-Martin West, Suite 550, Laval, Quebec, Canada H7M 3Y2 duly represented by Mr. Henri Harland, President and Chief Executive Officer (hereinafter referred to as "NEPTUNE"); And: Neuro Nutrition, Inc. having a place of business at 2475 Broadway, Suite 202, Boulder, CO 80304 represented by Mr. Michael Schuett, President (hereinafter referred to as "NEURO"); NEPTUNE and NEURO are hereinafter referred to as "Parties" in plural or singular usage as required by context. - -------------------------------------------------------------------------------- WHEREAS NEPTUNE is the sole owner of N

Valcent Products Inc. – Product Development Agreement (October 13th, 2005)

THIS PRODUCT DEVELOPMENT AGREEMENT ("Agreement") is made and entered into by and between MK ENTERPRISES LLC, a Nevada corporation having a place of business at 1300 Clay Street, Winfield, Louisiana 71483 (hereinafter referred to as "MK"), and VALCENT PRODUCTS, INC., an Alberta Canada corporation, having a place of business at Suite 420, 475 Howe Street, Vancouver, British Columbia, Canada (hereinafter referred to as "VPI"):

Accentia Biopharmaceuticals, Inc. – Product Development Agreement (April 6th, 2005)

THIS PRODUCT DEVELOPMENT AGREEMENT is made and entered into this 24th day of January, 2003 (the Effective Date) between Respirics, Inc., a Delaware corporation having an address at 6008 Triangle Drive, Suite 101, Raleigh, NC 27617 (hereinafter referred to as Respirics), and TEAMM Pharmaceuticals, a Delaware corporation and a wholly owned subsidiary of Accentia, Inc., a Florida corporation, having a primary address at 3000 Aerial Center Parkway, Suite 110, Morrisville, North Carolina 27560 (TEAMM).